2017
Progress in the Treatment of Hodgkin’s Lymphoma
Longo DL, DeVita VT. Progress in the Treatment of Hodgkin’s Lymphoma. New England Journal Of Medicine 2017, 378: 392-394. PMID: 29224505, DOI: 10.1056/nejme1715141.Peer-Reviewed Original Research
1999
The lymphomas.
DeVita V, Canellos G. The lymphomas. Seminars In Hematology 1999, 36: 84-94. PMID: 10595757.Peer-Reviewed Original Research
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDiseaseLymphomas.
Kwak L, DeVita V, Longo D. Lymphomas. 1994, 15: 413-70. PMID: 7779591.Peer-Reviewed Original Research
1993
CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma
Longo D, DeVita V, Young R. CHOP versus Intensive Regimens in Non-Hodgkin's Lymphoma. New England Journal Of Medicine 1993, 329: 580-582. PMID: 7687747, DOI: 10.1056/nejm199308193290817.Peer-Reviewed Original ResearchLymphomas.
Kwak L, DeVita V, Longo D. Lymphomas. 1993, 14: 383-426. PMID: 8312110.Peer-Reviewed Original Research
1991
The calculation of actual or received dose intensity: a comparison of published methods.
Longo D, Duffey P, DeVita V, Wesley M, Hubbard S, Young R. The calculation of actual or received dose intensity: a comparison of published methods. Journal Of Clinical Oncology 1991, 9: 2042-51. PMID: 1941063, DOI: 10.1200/jco.1991.9.11.2042.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesHumansLymphoma, Non-HodgkinMathematicsMiddle AgedPublishingConceptsSouthwest Oncology GroupTreatment courseEntire treatment coursePatient's treatment coursePrognostic factorsTreatment outcomesAggressive histology lymphomaCombination chemotherapy programsClinical prognostic factorsNational Cancer Institute studyDistinct patient populationsDose-related variablesDose intensityOncology GroupChemotherapy programPrognostic significancePatient populationStudy populationInstitute studyOutcomesRecent reportsEntire populationPopulationCourseDI dataLong-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology GroupSuperiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaCo-trimoxazole prophylaxisComplete response rateDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rateLymphomas.
Longo D, Devita V. Lymphomas. 1991, 12: 347-93. PMID: 1931450.Peer-Reviewed Original Research
1990
Lymphomas.
Longo D, DeVita V. Lymphomas. 1990, 11: 343-78. PMID: 2223399.Peer-Reviewed Original Research
1988
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.Peer-Reviewed Original ResearchConceptsResidual abdominal massesClinical complete remissionAbdominal massAggressive lymphomaNational Cancer InstituteStable residual massComplete remissionCombination chemotherapyPathologic evaluationFull-dose combination chemotherapyResidual massSubsequent tumor necrosisViable lymphoma cellsEvidence of diseaseMonths of chemotherapyInitial tumor sizeRestaging laparotomyBulky diseaseNegative laparotomyDisseminated diseaseIntraabdominal diseaseMost patientsSurgical explorationResidual tumorResidual diseaseThe treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment.
Young R, Longo D, Glatstein E, Ihde D, Jaffe E, DeVita V. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Seminars In Hematology 1988, 25: 11-6. PMID: 2456618.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCyclophosphamideDoxorubicinEtoposideEvaluation Studies as TopicHumansLeucovorinLeukemiaLeukemia, Radiation-InducedLymph NodesLymphoma, Non-HodgkinMechlorethamineMethotrexateNeoplasms, Multiple PrimaryNeoplasms, Radiation-InducedPalliative CarePrednisoneProcarbazineRandom AllocationVincristineConceptsAdvanced indolent lymphomaLimited radiation therapyTotal nodal irradiationIndolent lymphomaRadiation therapyModality treatmentInitial treatmentAggressive combined modality therapyCombined modality therapyEvaluable patientsInduction therapyInitial therapyNodal irradiationFirst remissionInitial remissionFrequent relapsesMedian durationModality therapySystemic therapyCombination chemotherapyMedian timeHistologic progressionLonger survivalPatient's diseasePatientsThe role of chemotherapy in diffuse aggressive lymphomas.
DeVita V, Hubbard S, Young R, Longo D. The role of chemotherapy in diffuse aggressive lymphomas. Seminars In Hematology 1988, 25: 2-10. PMID: 3041598.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsDrug EvaluationHumansLymphoma, Non-HodgkinPrognosisConceptsDiffuse aggressive lymphomasEarly-stage diseaseCombination chemotherapyAggressive lymphomaDose intensityNew combination chemotherapy programScheduling of drugsDurable complete remissionRole of chemotherapyCombination chemotherapy programsImportant prognostic factorEnd of treatmentComplete remissionStage diseaseChemotherapy programPrognostic factorsSubsequent radiotherapyRisk factorsPrimary treatmentAdditional drugsChemotherapyOld drugsAdvanced stageLymphomaRadiotherapyCytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapy
1987
The evolution of chemotherapy of lymphomas of adults.
DeVita V. The evolution of chemotherapy of lymphomas of adults. Leukemia 1987, 1: 467-85. PMID: 3312842.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyHodgkin DiseaseHumansLymphomaLymphoma, Non-HodgkinLymphomas.
Longo D, Devita V. Lymphomas. 1987, 9: 165-99. PMID: 3079402.Peer-Reviewed Original Research
1980
Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations
Come S, Jaffe E, Andersen J, Mann R, Johnson B, DeVita V, Young R. Non-Hodgkin's lymphomas in leukemic phase: Clinicopathologic correlations. The American Journal Of Medicine 1980, 69: 667-674. PMID: 7001897, DOI: 10.1016/0002-9343(80)90416-7.Peer-Reviewed Original ResearchConceptsPeripheral blood involvementBlood involvementHistologic subtypeLeukemic phaseAdult lymphoblastic lymphomaDiffuse large cell lymphomaNon-Hodgkin lymphomaLarge cell lymphomaHomogeneous clinical pictureTypes of NHLLymphoblastic lymphomaRappaport classificationClinical pictureClinicopathologic entityHodgkin's lymphomaNodular lymphomaUnresponsive diseaseClinicopathologic correlationLymphocytic lymphomaClinical subtypesLeukemic conversionCell lymphomaCytologic featuresHigh riskPredominant cellsThe Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications.
Garvin A, Simon R, Young R, DeVita V, Berard C. The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications. Seminars In Oncology 1980, 7: 234-43. PMID: 6998002.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsFemaleHumansLymphomaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMaleMiddle AgedConceptsLukes-Collins systemNon-Hodgkin's lymphomaLukes-CollinsClassification of non-Hodgkin's lymphomasClinical management of patientsAggressive combination chemotherapyDiffuse histiocytic lymphomaHomogeneous group of patientsManagement of patientsGroup of patientsB symptomsLymphocytic lymphomaCentroblastic-centrocyticCombination chemotherapyDiffuse lymphomaLymphoblastic lymphomaPlasmacytoid differentiationKiel classificationRappaport classificationNodular lymphomaHistiocytic lymphomaRetrospective reviewFollicular patternClinicopathologic entityYounger patients
1979
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
Brereton H, Young R, Longo D, Kirkland L, Berard C, Jaffe E, Devita V, Johnson R. A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma. Cancer 1979, 43: 2227-2231. PMID: 378350, DOI: 10.1002/1097-0142(197906)43:6<2227::aid-cncr2820430611>3.0.co;2-j.Peer-Reviewed Original Research